focus -WSS

focus

author：knowledge 2025-10-01 20:14:13 - browse：31987

Alex Hogan/STAT

SAN FRANCISCO — It seemed like there was a point during last year’s J.P. Morgan Healthcare Conference when we all collectively realized, “Oh, 2023 is going to be another slog.” Indeed, a downturn has weighed on the biotech industry for nearly three years.

But this January, things feel different. Maybe it’s the abundance of sunlight that filled San Francisco this week. More likely, it’s the surge of deals that came in December. Whatever the reason, sentiment around Union Square in recent days was markedly more positive this year.

Most everyone I spoke to this week noticed the change in tenor. “I’m feeling a lot of good energy, honestly,” Mira Chaurushiya, senior partner at VC Westlake Village BioPartners, told me Tuesday. “It’s not only what happened the last few weeks of the year, but what people are projecting moving forward.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： BioAge raises $170M for combination therapy with Zepbound

Wikipedia

WSS

What the Wegovy shortage looks like for doctors — and for patients

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Readout LOUD podcast: How biotech is using artificial intelligence

Peter Marks talks Operation Warp Speed for Rare Diseases

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

explore

focus

knowledge

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The Readout: Gilead, Bernie Sanders, and other pharma news

Supreme Court strikes down use of affirmative action

Eight reasons why you should get an updated Covid vaccine

Tori Bowie and the unacceptable rates of Black maternal death

To avoid data mishandling cases, universities eye AI and other tools

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Female surgeons have lower rates of long

Walensky prepares to leave CDC — and Congress — behind

A revolution in caring for preterm infants

explore

Akero's treatment for NASH falls short in cirrhosis study

To avoid data mishandling cases, universities eye AI and other tools

BioAge raises $170M for combination therapy with Zepbound

Gilead might be held responsible for not developing a drug

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Nick Jonas talks about managing diabetes along with his career

focus

Wikipedia

hotspot

hotspot